Laura A Vitale

US Patent:

20220324990, Oct 13, 2022

Filed:

Apr 14, 2022

Appl. No.:

17/720954

Inventors:

- Hampton NJ, US
Joel GOLDSTEIN - Hopewell NJ, US
Laura A. VITALE - Doylestown PA, US
Lizhen HE - Zhenghe County, Fujian, CN

International Classification:

C07K 16/28
A61P 35/00

Abstract:

Provided herein are anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain. Also provided herein are methods of stimulating T cell activity, methods of inducing or enhancing an immune response, and methods of treating a disease or condition by administering the bispecific constructs, antibodies, or antigen binding fragments thereof, or compositions described herein to a patient in need thereof.

US Patent:

20210147538, May 20, 2021

Filed:

Jan 8, 2021

Appl. No.:

17/145052

Inventors:

- Hampton NJ, US
Joel GOLDSTEIN - Hopewell NJ, US
Laura A. VITALE - Doylestown PA, US
Lizhen HE - Zhenghe County, Fujian, CN
Tom O'NEILL - Washington NJ, US
Andrea CROCKER - New Hope PA, US
Karuna SUNDARAPANDIYAN - Kendall Park NJ, US
Lawrence J. THOMAS - Easton MA, US
Jenifer WIDGER - Alpha NJ, US

Assignee:

Celldex Therapeutics, Inc. - Hampton NJ

International Classification:

C07K 16/28
A61K 39/395
A61K 39/385
C07K 14/54
C07K 14/715

Abstract:

Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

US Patent:

20200377606, Dec 3, 2020

Filed:

Apr 18, 2017

Appl. No.:

16/094737

Inventors:

- Hampton NJ, US
Joel GOLDSTEIN - Hopewell NJ, US
Laura A. VITALE - Doylestown PA, US
Lizhen HE - Allentown PA, US
Tom O'NEILL - Washington NJ, US
Andrea CROCKER - New Hope PA, US
Karuna SUNDARAPANDIYAN - Kendall Park NJ, US
Lawrence J. THOMAS - Easton MA, US
Jenifer WIDGER - Alpha NJ, US

International Classification:

C07K 16/28
A61K 39/395
A61K 39/385

Abstract:

Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

US Patent:

20200369768, Nov 26, 2020

Filed:

Aug 6, 2020

Appl. No.:

16/986613

Inventors:

- Hampton NJ, US
Joel GOLDSTEIN - Hopewell NJ, US
Laura A. VITALE - Doylestown PA, US
Lizhen HE - Allentown PA, US
Tom O'NEILL - Washington NJ, US
Andrea CROCKER - New Hope PA, US
Karuna SUNDARAPANDIYAN - Kendall Park NJ, US
Lawrence J. THOMAS - Easton MA, US
Jenifer WIDGER - Alpha NJ, US

International Classification:

C07K 16/28
A61K 39/395
C07K 14/54
C07K 14/715

Abstract:

Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

US Patent:

20200109207, Apr 9, 2020

Filed:

Apr 17, 2019

Appl. No.:

16/387228

Inventors:

- Hampton NJ, US
Joel GOLDSTEIN - Hopewell NJ, US
Laura A. VITALE - Doylestown PA, US
Lizhen HE - Allentown PA, US

International Classification:

C07K 16/28
A61P 35/00

Abstract:

Provided herein are novel anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain. Also provided herein are methods of stimulating T cell activity, methods of inducing or enhancing an immune response, and methods of treating a disease or condition (e.g., cancer) by administering the bispecific constructs, antibodies, or antigen binding fragments thereof, or compositions described herein to a patient in need thereof.

US Patent:

20190322743, Oct 24, 2019

Filed:

Apr 5, 2019

Appl. No.:

16/376585

Inventors:

- Hampton NJ, US
Joel GOLDSTEIN - Hopewell NJ, US
Laura A. VITALE - Doylestown PA, US
Lizhen HE - Allentown PA, US
Tom O'NEILL - Washington NJ, US
Andrea CROCKER - New Hope PA, US
Karuna SUNDARAPANDIYAN - Kendall Park NJ, US
Lawrence J. THOMAS - Easton MA, US
Jenifer WIDGER - Alpha NJ, US

International Classification:

C07K 16/28
C07K 14/715
C07K 14/54
A61K 39/395

Abstract:

Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

US Patent:

20180066053, Mar 8, 2018

Filed:

Apr 18, 2017

Appl. No.:

15/490589

Inventors:

- Needham MA, US
Joel GOLDSTEIN - Hopewell NJ, US
Laura A. VITALE - Doylestown PA, US
Lizhen HE - Allentown PA, US
Tom O'NEILL - Washington NJ, US
Andrea CROCKER - New Hope PA, US
Karuna SUNDARAPANDIYAN - Kendall Park NJ, US
Lawrence J. THOMAS - Easton MA, US
Jenifer Widger - Alpha NJ, US

International Classification:

C07K 16/28
C07K 14/715
C07K 14/54

Abstract:

Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

US Patent:

20180044429, Feb 15, 2018

Filed:

Mar 9, 2016

Appl. No.:

15/557035

Inventors:

- Needham MA, US
Joel GOLDSTEIN - Hopewell NJ, US
Lizhen HE - Allentown PA, US
Henry C. MARSH - Reading MA, US
Karuna SUNDARAPANDIYAN - Kendall Park NJ, US
Lawrence J. THOMAS - Easton MA, US
Laura A. VITALE - Doylestown PA, US
Jenifer WIDGER - Alpha NJ, US

International Classification:

C07K 16/28
C07K 16/30
C07K 14/705
A61K 39/00
A61K 39/395

Abstract:

The invention provides CD27 agonists comprising a first component that is an anti-CD27 antibody, or antigen-binding fragment thereof, linked to a second component comprising one or more cross-linking moieties. At least one of the cross-linking moieties does not bind to an Fc receptor and the CD27 agonist stimulates T cell activity without the need for Fc receptor interaction. The cross-linking molecule(s) can be, for example, an anti-CD27, antibody, or antigen-binding fragment thereof, that can be the same or different than the first component. Alternatively, the cross-linking molecule(s) can be a CD27 ligand or a molecule (e.g., antibody) that binds a molecule on a cell such as a T cell, a tumor cell or a stromal cell. Pharmaceutical compositions comprising the CD27 agonists, and methods of using the CD27 agonists, are also provided.